S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
A man fatally stabbed 4 family members before police shot and killed him; 2 officers injured
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Lacking counselors, US schools turn to the booming business of online therapy
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
A man fatally stabbed 4 family members before police shot and killed him; 2 officers injured
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Lacking counselors, US schools turn to the booming business of online therapy
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
A man fatally stabbed 4 family members before police shot and killed him; 2 officers injured
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Lacking counselors, US schools turn to the booming business of online therapy
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Breaches by Iran-affiliated hackers spanned multiple U.S. states, federal agencies say
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Chinese developer Evergrande risking liquidation if creditors veto its plan for handling huge debts
British military reports an explosion off the coast of Yemen in the key Bab el-Mandeb Strait
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Kiss say farewell to live touring, become first US band to go virtual and become digital avatars
A man fatally stabbed 4 family members before police shot and killed him; 2 officers injured
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Lacking counselors, US schools turn to the booming business of online therapy

Navidea Biopharmaceuticals Stock Price, News & Analysis (NYSE:NAVB)

$0.07
+0.02 (+40.08%)
(As of 12/1/2023 ET)
Compare
Today's Range
$0.05
$0.07
50-Day Range
$0.03
$0.10
52-Week Range
$0.02
$0.35
Volume
683,670 shs
Average Volume
338,672 shs
Market Capitalization
$7.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NAVB stock logo

About Navidea Biopharmaceuticals Stock (NYSE:NAVB)

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

NAVB Stock Price History

NAVB Stock News Headlines

Navidea Biopharmaceuticals, CRG Settle All Ongoing Litigation
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Navidea Biopharmaceuticals Inc NAVB
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
See More Headlines
Receive NAVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
12/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Employees
11
Year Founded
N/A

Profitability

Net Income
$-15,180,000.00
Pretax Margin
-860,700.00%

Debt

Sales & Book Value

Annual Sales
$70,000.00
Book Value
($0.03) per share

Miscellaneous

Free Float
56,367,000
Market Cap
$7.00 million
Optionable
Optionable
Beta
1.54
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Craig A. Dais CPA (Age 57)
    CFO & Principal Accounting Officer
  • Dr. Michael Sherman Blue F.A.C.E.P.
    M.D., Chief Medical Officer














NAVB Stock Analysis - Frequently Asked Questions

How have NAVB shares performed in 2023?

Navidea Biopharmaceuticals' stock was trading at $0.21 at the beginning of the year. Since then, NAVB stock has decreased by 66.7% and is now trading at $0.0699.
View the best growth stocks for 2023 here
.

How were Navidea Biopharmaceuticals' earnings last quarter?

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) announced its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.02) earnings per share (EPS) for the quarter.

Who are Navidea Biopharmaceuticals' major shareholders?

Navidea Biopharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Navidea Biopharmaceuticals?

Shares of NAVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:NAVB) was last updated on 12/3/2023 by MarketBeat.com Staff

My Account -